Product Description
Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20030420/)
Mechanisms of Action: 5-HT2A Antagonist,D2 Antagonist,D3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Japan | Korea
Approved Indications: None
Known Adverse Events: None
Company: Sumitomo Dainippon Pharma Co
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20222736 | N/A |
Completed |
Schizophrenia |
2022-12-07 |
|
| DSPCLON-002 | P4 |
Terminated |
Schizophrenia |
2022-11-22 |
|
| CTR20221635 | N/A |
Completed |
Schizophrenia |
2022-08-08 |
|
| CTR20212449 | N/A |
Completed |
Schizophrenia |
2021-12-17 |